Current Osteoporosis Reports

, Volume 16, Issue 2, pp 198–204 | Cite as

Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties

  • Matthew R. Allen
Biomechanics (G Niebur and J Wallace, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Biomechanics


Purpose of the Review

Bisphosphonates have well-established effects on suppressing bone resorption and slowing bone loss, yet the effects on bone mechanical properties are less clear. We review recent data from pre-clinical and clinical experiments that assessed mechanical properties of bisphosphonate-treated specimens.

Recent Findings

Pre-clinical work has utilized new techniques to show reduced fatigue life and transfer of stress from the mineral to collagen. Several notable studies have examined mechanical properties of tissue from patients treated with bisphosphonates with mixed results. Pre-clinical data suggest effects on mechanics may be independent of remodeling suppression.


The direct effect of bisphosphonates on bone mechanics remains unclear but recent work has set a solid foundation for the coming years.


Atypical fracture Zoledronate Remodeling suppression Anti-remodeling Biomechanics 


Funding Information

This work was supported by a United States (U.S.) Department of Veterans Affairs Merit Award (BX003025) and a NIH grant AR62002 to MRA.

Compliance with Ethical Standards

Conflict of Interest

Matthew Allen declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–301.CrossRefPubMedGoogle Scholar
  2. 2.
    Giusti A, Hamdy NAT, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy. Bone. Elsevier Inc. 2010;47:169–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27:2544–50.CrossRefPubMedGoogle Scholar
  4. 4.
    •• Ettinger B, Burr DB, Ritchie RO. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone. 2013;55(2):495–500. A high-level review of atypical femoral fractures with proposed mechanisms written by thought-leaders in the field. Google Scholar
  5. 5.
    Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1–23.CrossRefPubMedGoogle Scholar
  6. 6.
    Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60:324–33.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Allen MR. Preclinical models for skeletal research: how commonly used species mimic (or don’t) aspects of human bone. Toxicol Pathol. 2017;4:019262331773392–4.Google Scholar
  8. 8.
    Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don’t know. Bone. 2011;49:56–65.CrossRefPubMedGoogle Scholar
  9. 9.
    Mashiba T, Turner CH, Hirano T, Forwood M, Jacob D, Johnston C, et al. Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone. 2001;29:271–8.CrossRefPubMedGoogle Scholar
  10. 10.
    •• Kostenuik P. On the evolution and contemporary roles of bone remodeling. In: Marcus R, Feldman D, Dempster DW, Luckey M, Cauley JA, editors. Osteoporosis. 4th ed. Amsterdam: Academic Press; 2013. pp. 873–914. A review of pre-clinical studies focused on bisphosphonates (actually on anti-osteoporosis agents in general) and mechanical properties. CrossRefGoogle Scholar
  11. 11.
    Bajaj D, Geissler JR, Allen MR, Burr DB, Fritton JC. The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate. Bone. 2014;64:57–64.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Allen MR, Reinwald S, Burr DB. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int. 2008;82:354–60.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Acevedo C, Bale H, Gludovatz B, Wat A, Tang SY, Wang M, et al. Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. Bone. 2015;81:352–63.CrossRefPubMedGoogle Scholar
  14. 14.
    Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int. 2008;20:887–94.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int. 2007;19:329–37.CrossRefPubMedGoogle Scholar
  16. 16.
    Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int. 2008;19:1343–54.CrossRefPubMedGoogle Scholar
  17. 17.
    Jin A, Cobb J, Hansen U, Bhattacharya R, Reinhard C, Vo N, et al. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. Bone Joint Res. 2017;6:602–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ma S, Goh EL, Jin A, Bhattacharya R, Boughton OR, Patel B, et al. Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. Sci Rep Nat Publ Group. 2017:1–10.Google Scholar
  19. 19.
    •• Zimmermann EA, Schaible E, Gludovatz B, Schmidt FN, Riedel C, Krause M, et al. Intrinsic mechanical behavior of femoral cortical bone in young, osteoporotic and bisphosphonate- treated individuals in low- and high energy fracture conditions. Sci Rep Nat PublGroup. 2016:1–12. Detailed mechanical assessment of clinical tissue from bisphosphonate (and control) treated individuals.
  20. 20.
    Krause M, Soltau M, Zimmermann EA, Hahn M, Kornet J, Hapfelmeier A, et al. Effects of long-term alendronate treatment on bone mineralisation, resorption parameters and biomechanics of single human vertebral trabeculae. Eur Cell Mater. 2014;28:152–63. discussion163–5CrossRefPubMedGoogle Scholar
  21. 21.
    •• Lloyd AA, Gludovatz B, Riedel C, Luengo EA, Saiyed R, Marty E, et al. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci U S A. 2017;49:201704460–6. Detailed mechanical assessment of clinical tissue from bisphosphonate (and control)-treated individuals. A sub-set of these samples were from patients who experienced atypical femoral fractures—the only data that currently exists from such patients. Google Scholar
  22. 22.
    Ward J, Wood C, Rouch K, Pienkowski D, Malluche HH. Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates. Osteoporos Int. 2016;27(9):2681–2688.Google Scholar
  23. 23.
    Allen MR, McNerny EM, Organ JM, Wallace JM. True gold or pyrite: a review of reference point indentation for assessing bone mechanical properties in vivo. J Bone Miner Res. 2015;30:1539–50.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Nogues X, Prieto-Alhambra D, Güerri-Fernández R, Garcia Giralt N, Rodriguez-Morera J, Cos L, et al. Fracture during oral bisphosphonate therapy is associated with deteriorated bone material strength index. Bone. 2017;103:64–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Güerri-Fernández RC, Nogués X, Quesada Gómez JM, Torres del Pliego E, Puig L, García-Giralt N, et al. Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res. 2012;28:162–8.CrossRefGoogle Scholar
  26. 26.
    Aref MW, McNerny EMB, Brown D, Jepsen KJ, Allen MR. Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes. Osteoporos Int. 2016;27:3637–43.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lin J. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18:75–85.CrossRefPubMedGoogle Scholar
  28. 28.
    Turek J, Ebetino FH, Lundy MW, Sun S, Kashemirov BA, Mckenna CE, et al. Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits. Calcif Tissue Int. 2012;90:202–10.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Departments of Anatomy and Cell Biology, Medicine-Nephrology and Orthopaedic SurgeryIndiana University School of MedicineIndianapolisUSA
  2. 2.Department of Biomedical EngineeringIndiana University Purdue University of IndianapolisIndianapolisUSA
  3. 3.Roudebush Veterans Administration Medical CenterIndianapolisUSA

Personalised recommendations